Identify Candidates for COVID-19 Monoclonal Antibodies

Bamlanivimab/etesevimab will be the third monoclonal antibody option authorized to treat OUTpatients with COVID-19.

This combo joins bamlanivimab and casirivimab/imdevimab as another single-dose IV infusion. And more are in the works.

These "mabs" block SARS-CoV-2 from entering cells. Combo products may also limit treatment-emergent resistant viral variants.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals